In a boost for Sarepta Therapeutics (SRPT), the last remaining large health insurer has agreed to cover its pricey treatment for a rare form of muscular dystrophy.
In a policy bulletin issued on Thursday, Anthem (ANTM) declared Exondys 51 to be “medically necessary,” reversing a decision made a year ago not to reimburse the drug, which had just been approved to treat Duchenne muscular dystrophy amid controversy about underlying clinical data.
About the Author Reprints
My son Shivam Anjay age 19 years patient of DMD needs treatment by sarepta Exondys 51, when this medicine will be available in India or if I want to get treatment at USA what cost I have to bear, pl help and guide me.